
A Leiden family study linked four plasma proteins to survival and cardiometabolic health. The findings identify research candidates, not clinical tests.

On November 13, 2026, researchers working with the Leiden Longevity Study published an analysis of plasma proteins and multigenerational longevity in EBioMedicine.
According to the study summary, gelsolin (GSN), prothrombin (F2), cartilage acidic protein 1 (CRTAC1) and haptoglobin (HP) were consistently associated with longer survival in both generations. The same four proteins were associated with more years of cardiometabolic health and with familial longevity. The central finding is that overlap: these proteins appeared across analyses of survival, health and family longevity rather than in only one comparison.
Evidence level: Human observational research involving long-lived siblings, their offspring and their partners.
The summary describes 852 siblings aged 89 or older and 2,282 offspring and partners aged between 30 and 80. The older siblings formed the long-lived generation in the analysis. The offspring and partners provided another generation in which researchers examined associations between plasma proteins and later outcomes.
For the familial-longevity comparison, researchers compared offspring of the long-lived siblings with their partners. That comparison addressed a different question from survival during follow-up. It examined whether the protein findings were also associated with being in the offspring group within this family-based cohort.
Keeping those questions separate helps explain the study's design. An association with survival concerns an outcome observed over time. An association with familial longevity concerns the comparison between offspring and partners. The study summary reports that the four proteins featured in both types of analysis.
The researchers measured 326 proteins in blood plasma, according to the summary. The four highlighted proteins therefore came from a broader set of measurements. Their importance in this report rests on their consistent associations across the reported outcomes, rather than simply on their presence in blood.
The follow-up also covered different periods for different outcomes. Researchers examined survival over as many as 22 years and years of cardiometabolic health over as many as 16 years. Those figures describe the observation windows used for the two outcomes. They should remain attached to their respective outcomes when the findings are summarized.
Survival and cardiometabolic health give the report two related perspectives on aging. The survival analysis concerns how long participants lived during observation. The cardiometabolic analysis concerns years of health in that measured area. Together they place the protein findings within both longevity research and research on time spent healthy.
The multigenerational result adds another useful distinction. The survival associations appeared in both generations, while the familial comparison specifically involved offspring and partners. Reading those findings together captures the study's central contribution: a shared set of protein associations across generations and across related questions about health and survival.
For readers comparing longevity headlines, a useful approach is to identify the population first, then the measurement and finally the outcome. Here the population was a family-based cohort. The measurements were plasma proteins. The outcomes included survival and cardiometabolic health, alongside the familial-longevity comparison.
That approach provides a consistent basis for assessing reports that might otherwise seem to conflict. Ask whether studies address the same question before comparing their conclusions. Keeping the outcome being measured in view is useful, as is distinguishing human observations from laboratory experiments. For this report the appropriate starting point is a human family-cohort association.
These boundaries give readers a practical way to place the findings. When encountering a claim based on this study, check whether it preserves the family-cohort context and names the actual outcome. Then distinguish a research association from a proposed clinical use. That reading approach allows the result to remain scientifically interesting without assigning it a role the evidence has not established.
The next phase should test these associations in independent populations and determine whether the proteins add useful information beyond health differences already present at the start.
Blood-protein headlines can blur the difference between a family-study association and a useful health test. AgeAmaze helps research-minded adults sort conflicting longevity reports with accessible explanations of biomarkers and healthy aging, so the question a study asked stays connected to the conclusion it supports.
Stay current with research on aging biology, biomarkers, nutrition, therapeutics, peptides and longevity technology. AgeAmaze reports what the evidence shows, where uncertainty remains and which claims still need stronger data.



Follow AgeAmaze for careful reporting on what longevity science can show today and what still needs stronger evidence.
read the Blog